ProShare Advisors’s Soleno Therapeutics SLNO Stock Holding History

ProShare Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,303	Closed	-$245K	–	2009
2026 Q1	$245K	Sell	7,303 -1,219	-14%	-$47.8K	﹤0.01%	1454
2025 Q4	$395K	Buy	8,522 +1,380	+19%	+$75.7K	﹤0.01%	1274
2025 Q3	$483K	Sell	7,142 -1,097	-13%	-$81.3K	﹤0.01%	1130
2025 Q2	$690K	Buy	8,239 +2,700	+49%	+$202K	﹤0.01%	951
2025 Q1	$396K	Sell	5,539 -1,667	-23%	-$81.2K	﹤0.01%	1221
2024 Q4	$324K	Buy	7,206 +2,836	+65%	+$147K	﹤0.01%	1573
2024 Q3	$221K	Buy	+4,370	New	+$209K	﹤0.01%	1670
2021 Q2	–	Sell	-1,075	Closed	-$20K	–	2398
2021 Q1	$20K	Buy	1,075 +195	+22%	+$6.29K	﹤0.01%	2257
2020 Q4	$25K	Buy	+880	New	+$25.4K	﹤0.01%	2081

ProShare Advisors's SLNO Position: Q2 2026 in Review

ProShare Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 7,303 shares — an estimated $245K sold.

ProShare Advisors first reported a position in SLNO in Q4 2020 and held it in 9 quarters. The position peaked at $690K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

ProShare Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
ProShare Advisors sold 7,303 Soleno Therapeutics shares in Q2 2026, an estimated $245K.
ProShare Advisors first reported a position in Soleno Therapeutics in Q4 2020 and held it in 9 quarters.
ProShare Advisors's Soleno Therapeutics position peaked at $690K in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.